Sotorasib is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ... The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $267.10. Discover ...

A dozen wake Technical Community College students signed letters of intent on Monday to work with Amgen. Amgen is planning a $1 billion expansion in Holly Springs. “This is a really good ...